ADD - The 20-Hour Solution - Mark Steinberg - [EPUB][N27]seeders: 16
leechers: 3
ADD - The 20-Hour Solution - Mark Steinberg - [EPUB][N27] (Size: 1.39 MB)
DescriptionADD: The 20-Hour Solution by Mark Steinberg, Siegfried Othmer English | EPUB | ISBN-10: 1931741379 | ISBN-13: 978-1931741378 February 4, 2013 | Robert D. Reed Publishers  Counseling & Psychology, Adolescent Psychology CONTENTS About the Authors Foreword Introduction ADD/ADHD Demystified The ADD Merry-Go-Round: Matthew’s Story How EEG Neurofeedback Addresses ADD/ADHD Neurotherapy: Training the Brain with Computers Assessing Children and Monitoring Progress toward Mental Fitness Accessing Resources and Making It Happen What You Can Do: A Parent’s Guide The Cult of the Neurotransmitter: A Philosophy of Self-Control and Responsibility for Behavior Taming the Tempest: The Othmers’ Story Epilogue Case Histories Commentary on the Psychiatric Classification of ADD/ADHD Excerpt: The ADD/ADHD Enigma Almost everyone has heard of ADD/ADHD[1]. Most people have opinions about it; some have very strong, even stubborn, opinions. It is common to know people with ADD, or to find out that someone you know has ADD — perhaps even someone in your family. Whether communicated by relieved announcement or decried through hushed whispers, ADD tends to stir emotions and attitudes in those who live with it or around it. This condition — presumably a deficiency of attention — draws ironically to itself a remarkable amount of attention, as if to make up for its namesake. There are ADD organizations, ADD pharmaceuticals, laws about ADD, treatments for it, diagnostic guidelines — yet, there is little agreement (in the broad consensus) about what ADD is, how to diagnose it, and how to treat it. Though the medical mainstream would like to present a unity about ADD, this condition eludes easy categorization and cure through medicine. In recent years, the pharmaceutical monolith has prevailed, justifying the prolific use of drugs to counteract an imputed biochemical imbalance. Despite the impact of the pharmaceutical approach (along with its convenience and its staggering profits for the drug manufacturers), there is little evidence that ADD can be pinpointed as a unitary disease of enzymes or neurotransmitters or microorganisms, easily targeted and controlled by external (and patented) substances. Sharing Widget |